Tokyo, Japan - September 30, 2021 - Medical & Biological Laboratories Co., Ltd. (MBL), a JSR Life Sciences Company, has signed a distributor agreement with Qkine Ltd. for sale of products in Japan.
In recent years, there has been an increasing need for reagents that meet the high biological raw materials standards for the development of products such as regenerative medicines. MBL’s production system complies with the international standards (ISO13485) for quality management systems for medical devices and has extensive experience in providing custom service products with a certificate of conformity (or non-applicability). Through this agreement, MBL will expand its lineup of research products that meet the standards for biological raw materials, such as niche factors for organoid culture.
Qkine combines proprietary manufacturing processes developed at the University of Cambridge with protein engineering techniques to produce high-purity, animal-free recombinant proteins optimized for stem cell culture in its Animal-Derived Component Free (ADCF) lab. The company has also supported research and development in the fields of stem cells, cell organs, and regenerative medicine by providing high-quality proteins that have passed extremely strict and robust quality control standards.
Contact details
-
- Missy Bindseil
-
JSR Life Sciences Company Inquiries
Director, Marketing & Communications - mbindseil@jsr-nahq.com
Related topics
Related news
MBL Co-sponsors a Seminar on MEBRIGHT™ genitalium Plus DR Kit at the 98th JAID / the 72nd JSC Conference
MBL to co-sponsor a seminar on MEBRIGHT™ genitalium Plus DR Kit at the 98th JAID/72nd JSC Conference, focusing on STD treatment advancements. Learn more on June 27th, 2024.
MBL announces exclusive license agreement for Anti-Integrin αvβ6 Antibody with Immune-related Adverse Events colitis
MBL has announced that it has entered into an exclusive license agreement with Kyoto University and Kindai University regarding the detection of Anti-Integrin αvβ6 autoantibodies as an indicator of...
MEBGEN™ BRAF 2 Kit Receives MHLW Approval as a Companion Diagnostic for Use with Patients with Thyroid Cancer
With this approval, the MEBGEN™ BRAF 2 Kit is expected to contribute to the timely personalized treatment for patients with radically unresectable thyroid cancer based on the presence or absence of...
Notice of Approval for First-Class Marketing License for Medical Devices
With the acquisition of the First-Class Marketing License for Medical Devices, MBL will be able to market highly controlled medical devices, including genetic testing systems using NGS.
Launch of a New Chemiluminescence Immunoassay Analyzer “iStar500”
The iStar is a highly automated mono-test analyzer based on CLIA technology. The compact & integrated design, combined with highly sensitive CLIA technology, makes it an ideal choice for emergency ...